| Full Name | Targeting Protein For Xklp2 (Microtubule Nucleation Factor) |
|---|---|
| Chromosomal Location | 12q23.2 |
| NCBI Gene ID | 22974 |
| OMIM | 604202 |
| Ensembl ID | ENSG00000178999 |
| UniProt ID | Q9ULW0 |
| Protein | TPX2 protein |
| Associated Diseases | Cancer (multiple types), Aneuploidy, Mitotic defects |
TPX2 is a human gene whose product tPX2 (Targeting Protein for Xklp2) is a microtubule-associated protein that functions as a key regulator of microtubule nucleation during mitosis[1]. It plays critical roles in spindle assembly, chromosome alignment, and proper cell division. Variants in TPX2 have been implicated in Cancer, Neurodegeneration. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
TPX2 (Targeting Protein for Xklp2) is a microtubule-associated protein that functions as a key regulator of microtubule nucleation during mitosis[1:1]. It plays critical roles in spindle assembly, chromosome alignment, and proper cell division.
TPX2 is regulated by:
TPX2 expression is cell cycle-regulated:
Brain expression:
Wittmann T, et al. TPX2 microtubule nucleation. J Cell Biol. 2000. ↩︎ ↩︎
Tulu US, et al. TPX2 and gamma-TuRC. Curr Biol. 2006. ↩︎
Tsai MY, et al. TPX2 activates Aurora A. Nat Cell Biol. 2003. ↩︎
Mayer TU, et al. TPX2 inhibits kinesin-5. Science. 1999. ↩︎
O'Brien PM, et al. TPX2 in chromosome alignment. 2008. ↩︎
Eyers PA, et al. TPX2 phosphorylation. 2003. ↩︎
Caudron M, et al. Ran gradient and TPX2. 2005. ↩︎
Schwoerer J, et al. TPX2 nuclear import. 2004. ↩︎
Gingold EB, et al. TPX2 in cancer. 2014. ↩︎
Suitters AJ, et al. TPX2 as prognostic marker. 2007. ↩︎
Tan MJ, et al. TPX2 therapeutic target. 2015. ↩︎
Baas PW, et al. Microtubules in AD. 2003. ↩︎
Liu C, et al. TPX2 in tauopathies. 2014. ↩︎
Mandelkow E, et al. Axonal transport defects. 2003. ↩︎
Lucchesi J, et al. Cell cycle regulation of TPX2. 2003. ↩︎
Wang D, et al. TPX2 in neural progenitors. 2009. ↩︎
Zhou J, et al. Aurora kinase inhibitors and TPX2. 2011. ↩︎
Kolman A, et al. Anti-mitotic therapy. 2014. ↩︎
Khazaei MR, et al. TPX2 in combination therapy. 2015. ↩︎